Developer docs
API playgroundTry for free, no card

Search company profiles

Acarix

Full company profile

uuid0005xvi

Namestring
Acarix
Legal namestring
Acarix AB (publ)
Websiteurl
acarix.com
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMalmö, Sweden
HQ citystring
Malmö
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac diagnostic devices, coronary artery disease, point-of-care diagnostics, acoustic cardiac monitoring, medical device manufacturing
Industry1 code
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Diagnostic Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CADScor System Device Sales
TypeHardware Sales
Description

Sale of CADScor medical device systems to healthcare providers, hospitals, and cardiology practices. Q4 2025 saw 23 CADScor Systems delivered, representing 64% growth in device deliveries worldwide.

in.investing.com
2CADScor Patch Consumables
TypeUsage Based
Description

Recurring revenue from disposable CADScor patches used during patient assessments. System has been used in over 60,000 patient assessments since 2017 commercial launch.

acarix.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Enterprise medical device with recurring consumable revenue
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed. Revenue model combines device system sales with recurring patch consumables. Q4 2025 total revenue was SEK 2,141 thousand.

in.investing.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Acarix develops and sells the CADScor System, a point-of-care medical device that uses ultrasensitive acoustic recording (phonocardiography) and an integrated CAD-Score Algorithm to analyze heart sounds and rapidly rule out significant coronary artery disease (CAD) in symptomatic patients. The system is paired with disposable CADScor Patch sensors and produces a patient-specific CAD-score (0-99) in approximately 10 minutes for immediate risk stratification prior to secondary evaluation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 96.2% negative predictive value in United States, 97.2% in European markets
+4 more records
Product overview1 text field

Acarix offers the CADScor System as its core medical device product, a point-of-care diagnostic aid for ruling out significant coronary artery disease. The system combines a hardware device with a disposable CADScor Patch sensor and an integrated CAD-Score Algorithm developed with Aalborg University. The product provides rapid (10-minute), non-invasive, radiation-free assessment using acoustic analysis of heart sounds, producing a numerical CAD-score (0-99) for risk stratification. The portfolio is supported by a comprehensive clinical studies program demonstrating the system's performance across over 8,000 patients.

Product and service2 records
1CADScor System
CategoryCardiac Diagnostic Device
Description

Point-of-care diagnostic aid that uses highly sensitive acoustics (phonocardiography) and advanced computational processing to analyze coronary blood flow and rule out significant coronary artery disease. Calculates a patient-specific CAD-score (0-99) coupled with risk factors for immediate risk stratification prior to secondary evaluation. For cardiology practices, hospitals, and cardiac units evaluating symptomatic patients with suspected CAD.

2CADScor Patch
CategoryMedical Device Consumable / Accessory
Description

Disposable sensor patch used with the CADScor System for recording heart sounds. Contains a specific chip and code required to calibrate the machine. Each patch can be used up to four times if not removed from the patient's chest. Generates recurring consumable revenue tied to patient assessment volume.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Saudi Arabia Distribution Partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-11
Description

Strategic distribution partnership for CADScor System in Saudi Arabia targeting regulatory approval and product orders worth approximately SEK 9.8 million within six months after approval. Part of MENA region expansion strategy.

tradingview.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative development of the integrated scoring algorithm for CADScor System. University partnership providing academic and research credibility for the acoustic detection technology and algorithm development.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Media relations contact for press inquiries. Contact: Macie May at acarix@saxum.com, phone +1 405 517 5161.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Philips provides comprehensive cardiac care solutions including imaging, monitoring, and AI-enabled diagnostic tools. As a broad incumbent, it competes for the same cardiology customer relationships and capital purchasing decisions that Acarix targets with its point-of-care CADScor system.

TypeBroad incumbent
Description

Boston Scientific is a major cardiovascular device company with cardiac diagnostics and monitoring (including its acquisition of Preventice Solutions). It competes in the broader cardiac care space and could be a potential strategic acquirer for Acarix given complementary cardiac monitoring capabilities.

TypeEmerging player
Description

Cardio Diagnostics offers AI-driven epigenetic and genetic blood tests for cardiovascular disease risk assessment. Both companies are early-stage, AI-powered cardiac diagnostics targeting similar clinical decision points, though Cardio Diagnostics uses blood-based biomarkers while Acarix uses acoustic sensing.

TypeDirect peer
Description

Cleerly applies AI to coronary CT angiography for plaque characterization and CAD risk assessment. Both companies offer AI-powered CAD diagnostic aids aimed at improving risk stratification and reducing unnecessary invasive procedures, though Cleerly is imaging-based while CADScor is acoustic-based.

TypeDirect peer
Description

HeartFlow provides non-invasive FFR-CT analysis for coronary artery disease assessment. Both companies target rapid CAD rule-out at point of care or in diagnostic workflows, competing for the same cardiology practice customers and hospital budgets, though HeartFlow uses CT imaging while Acarix uses acoustic sensing.

TypeEmerging player
Description

Viz.ai applies AI to cardiovascular and neurovascular care coordination and diagnostics. Both companies are AI-focused medical technology players targeting improved clinical decision-making in cardiac care, though Viz.ai focuses on care coordination and stroke while Acarix focuses on CAD rule-out.

TypeDirect peer
Description

iRhythm's Zio patch is a wearable adhesive cardiac monitoring patch. Both companies use patch-based cardiac diagnostic technology sold to cardiology practices, though iRhythm focuses on arrhythmia detection (Holter-style) while Acarix focuses on CAD rule-out.

TypeEmerging player
Description

AliveCor provides AI-powered portable ECG devices (KardiaMobile) for cardiac monitoring. Both companies offer non-invasive, AI-enabled cardiac diagnostic tools for point-of-care use, though AliveCor focuses on arrhythmia detection via single-lead ECG rather than CAD detection.

TypeBroad incumbent
Description

GE HealthCare is a major medical imaging and cardiac diagnostics incumbent offering CT, MRI, and nuclear cardiology solutions. As a broad cardiac diagnostic portfolio player, it competes with Acarix for hospital cardiology budgets and represents the incumbent alternative to novel point-of-care solutions.

TypeEmerging player
Description

Elucid offers AI-enabled vascular imaging analysis for cardiovascular disease assessment. Both companies apply AI to non-invasive cardiac/vascular diagnostics targeting improved risk stratification, though Elucid focuses on imaging-based plaque analysis.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acarix

Cardiac Diagnostic Devicesacarix.com

Acarix firmographics

Firmographics
Name
Acarix
Legal name
Acarix AB (publ)
Website
https://acarix.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Acarix industry classification

Industry
Product category
Cardiac Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Cardiac diagnostic devices
  • Coronary artery disease
  • Point-of-care diagnostics
  • Acoustic cardiac monitoring
  • Medical device manufacturing

Where Acarix is headquartered

Location

Headquarters

HQ city
Malmö
HQ country
Sweden
HQ region
Europe

Offices4 records

Markets served

Acarix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. CADScor System Device Sales: Sale of CADScor medical device systems to healthcare providers, hospitals, and cardiology practices. Q4 2025 saw 23 CADScor Systems delivered, representing 64% growth in device deliveries worldwide.
  2. CADScor Patch Consumables: Recurring revenue from disposable CADScor patches used during patient assessments. System has been used in over 60,000 patient assessments since 2017 commercial launch.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goEnterprise medical device with recurring consumable revenue

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Acarix product offering

Product offering

Core offering

Acarix develops and sells the CADScor System, a point-of-care medical device that uses ultrasensitive acoustic recording (phonocardiography) and an integrated CAD-Score Algorithm to analyze heart sounds and rapidly rule out significant coronary artery disease (CAD) in symptomatic patients. The system is paired with disposable CADScor Patch sensors and produces a patient-specific CAD-score (0-99) in approximately 10 minutes for immediate risk stratification prior to secondary evaluation.

Product overview

Acarix offers the CADScor System as its core medical device product, a point-of-care diagnostic aid for ruling out significant coronary artery disease. The system combines a hardware device with a disposable CADScor Patch sensor and an integrated CAD-Score Algorithm developed with Aalborg University. The product provides rapid (10-minute), non-invasive, radiation-free assessment using acoustic analysis of heart sounds, producing a numerical CAD-score (0-99) for risk stratification. The portfolio is supported by a comprehensive clinical studies program demonstrating the system's performance across over 8,000 patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • CADScor System Point-of-care diagnostic aid that uses highly sensitive acoustics (phonocardiography) and advanced computational processing to analyze coronary blood flow and rule out significant coronary artery disease. Calculates a patient-specific CAD-score (0-99) coupled with risk factors for immediate risk stratification prior to secondary evaluation. For cardiology practices, hospitals, and cardiac units evaluating symptomatic patients with suspected CAD.
  • CADScor Patch Disposable sensor patch used with the CADScor System for recording heart sounds. Contains a specific chip and code required to calibrate the machine. Each patch can be used up to four times if not removed from the patient's chest. Generates recurring consumable revenue tied to patient assessment volume.

Quantifiable outcome

  • 96.2% negative predictive value in United States, 97.2% in European markets
  • +4 more outcomes

Companies that use Acarix

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Acarix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Acarix partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Saudi Arabia Distribution PartnercoreChannel Partner/ Reseller/ Distributor · 11 February 2026Strategic distribution partnership for CADScor System in Saudi Arabia targeting regulatory approval and product orders worth approximately SEK 9.8 million within six months after approval. Part of MENA region expansion strategy.
  • Aalborg UniversitycoreStrategic or Co-development PartnerCollaborative development of the integrated scoring algorithm for CADScor System. University partnership providing academic and research credibility for the acoustic detection technology and algorithm development.
  • Saxum (Media Relations)minorGTM or Marketing PartnerMedia relations contact for press inquiries. Contact: Macie May at acarix@saxum.com, phone +1 405 517 5161.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Acarix competitors and assessment

Company assessment

Broad incumbents

  • Philips (Cardiac Care): Philips provides comprehensive cardiac care solutions including imaging, monitoring, and AI-enabled diagnostic tools. As a broad incumbent, it competes for the same cardiology customer relationships and capital purchasing decisions that Acarix targets with its point-of-care CADScor system.
  • Boston Scientific: Boston Scientific is a major cardiovascular device company with cardiac diagnostics and monitoring (including its acquisition of Preventice Solutions). It competes in the broader cardiac care space and could be a potential strategic acquirer for Acarix given complementary cardiac monitoring capabilities.
  • GE HealthCare: GE HealthCare is a major medical imaging and cardiac diagnostics incumbent offering CT, MRI, and nuclear cardiology solutions. As a broad cardiac diagnostic portfolio player, it competes with Acarix for hospital cardiology budgets and represents the incumbent alternative to novel point-of-care solutions.

Emerging players

  • Cardio Diagnostics Holdings: Cardio Diagnostics offers AI-driven epigenetic and genetic blood tests for cardiovascular disease risk assessment. Both companies are early-stage, AI-powered cardiac diagnostics targeting similar clinical decision points, though Cardio Diagnostics uses blood-based biomarkers while Acarix uses acoustic sensing.
  • Viz.ai: Viz.ai applies AI to cardiovascular and neurovascular care coordination and diagnostics. Both companies are AI-focused medical technology players targeting improved clinical decision-making in cardiac care, though Viz.ai focuses on care coordination and stroke while Acarix focuses on CAD rule-out.
  • AliveCor: AliveCor provides AI-powered portable ECG devices (KardiaMobile) for cardiac monitoring. Both companies offer non-invasive, AI-enabled cardiac diagnostic tools for point-of-care use, though AliveCor focuses on arrhythmia detection via single-lead ECG rather than CAD detection.
  • Elucid Bioimaging: Elucid offers AI-enabled vascular imaging analysis for cardiovascular disease assessment. Both companies apply AI to non-invasive cardiac/vascular diagnostics targeting improved risk stratification, though Elucid focuses on imaging-based plaque analysis.

Direct peers

  • Cleerly: Cleerly applies AI to coronary CT angiography for plaque characterization and CAD risk assessment. Both companies offer AI-powered CAD diagnostic aids aimed at improving risk stratification and reducing unnecessary invasive procedures, though Cleerly is imaging-based while CADScor is acoustic-based.
  • HeartFlow: HeartFlow provides non-invasive FFR-CT analysis for coronary artery disease assessment. Both companies target rapid CAD rule-out at point of care or in diagnostic workflows, competing for the same cardiology practice customers and hospital budgets, though HeartFlow uses CT imaging while Acarix uses acoustic sensing.
  • iRhythm Technologies: iRhythm's Zio patch is a wearable adhesive cardiac monitoring patch. Both companies use patch-based cardiac diagnostic technology sold to cardiology practices, though iRhythm focuses on arrhythmia detection (Holter-style) while Acarix focuses on CAD rule-out.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Acarix social profiles

Digital presence

Acarix compliance and trust

Trust signal

Compliance2 records

Acarix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acarix leadership team

Management profile

Number of profiles

Profiles8 records

Acarix subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Acarix funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acarix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acarix

What does Acarix do?

Acarix develops and sells the CADScor System, a point-of-care medical device that uses ultrasensitive acoustic recording (phonocardiography) and an integrated CAD-Score Algorithm to analyze heart sounds and rapidly rule out significant coronary artery disease (CAD) in symptomatic patients. The system is paired with disposable CADScor Patch sensors and produces a patient-specific CAD-score (0-99) in approximately 10 minutes for immediate risk stratification prior to secondary evaluation.

Is Acarix a public or private company?

Acarix is a public company. It is classified as public and is currently operating.

When was Acarix founded?

Acarix was founded in 2015. It employs 11 to 50 people.

Where is Acarix based?

Acarix is headquartered in Malmö, Sweden, in the Europe region.

How does Acarix make money?

Two revenue lines are on record. CADScor System Device Sales are the primary driver. The others are CADScor Patch Consumables.

Who are Acarix's main competitors?

Broad incumbents on record are Philips (Cardiac Care), Boston Scientific and GE HealthCare. Emerging players are Cardio Diagnostics Holdings, Viz.ai, AliveCor and Elucid Bioimaging. Direct peers are Cleerly, HeartFlow and iRhythm Technologies.

Does Acarix have an API?

No public API is recorded for Acarix.

What industry is Acarix in?

Acarix's product category is Cardiac Diagnostic Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dagens industriAcarix rörelseförlust minskarAcarix reported an operating loss of 7.5 million Swedish kronor in the third quarter of 2026, down from 8.9 million in the prior period. The company, which develops technology for detecting coronary artery disease, posted the loss on its first North-listed status.BioSpacePeer-Reviewed Study Confirms CADScor System Can Diagnose Heart Failure With Far Fewer False Positives Than Standard Blood TestAcarix announced a peer-reviewed study in PLOS Digital Health showing its CADScor System's seismocardiography can detect heart failure with accuracy comparable to NT-proBNP but fewer false positives. The study found the HFrEF-score had 92.9% AUC vs 94.7% for NT-proBNP, with higher specificity and positive predictive value. The HF algorithm is investigational and requires FDA approval.AInvestThe Growth Number That Doesn't Tell You What to DoAcarix AB reported a 102% increase in Q2 2026 revenue, driven by a surge in US system deliveries and clinical adoption of its CADScor device. The company is currently pursuing permanent CPT I reimbursement classification from CMS to improve economics, as current provisional billing yields significantly lower revenues.AInvestRevenue Doubled. Burn Dropped. And Then You Look at the Denominator.Acarix AB reported a 102% year-over-year revenue increase to SEK 2.3 million in Q2 2026, driven by a 212% surge in U.S. sales and a 19% reduction in operating costs. Despite these operational improvements, the company faces significant dilution risks with cash runway extending only to Q2 2027 due to cumulative share dilution of approximately 233% since 2023. The firm is currently awaiting CMS approval for a CPT I reimbursement code transition expected in H1 2027, which could significantly improve margins from the current ~$60 per test rate.YahooAcarix AB (ACIXF) (Q2 2026) Earnings Call Highlights: Revenue Surges 102% on Strong US Growth ...Acarix AB reported a 102% year-over-year revenue increase in Q2 2026, driven by strong growth in the United States market and the completion of enrollment for its U.S. performance trial. The company secured regulatory approval in the UAE to enter the Gulf region with partner Unitec Solutions while simultaneously reducing operating expenses by 19%. Despite these gains, gross margins declined due to a shift toward lower-margin hardware sales, and the timeline for favorable CPT1 reimbursement codes remains uncertain pending CMS review.Seeking AlphaAcarix AB (publ) (ACIXF) Q2 2026 Earnings Call Prepared Remarks TranscriptAcarix AB reported on its Q2 2026 earnings, highlighting the regulatory approval of its CADScor System in the United Arab Emirates, marking the company's entry into the Gulf region. The company continues to leverage its FDA-approved and CE-marked acoustic device, which has performed over 60,000 assessments globally with a high negative predictive value for ruling out coronary artery disease.Investing.comEarnings call transcript: Acarix posts strong Q2 2026 growth as stock slips By Investing.comAcarix reported a 102% year-over-year revenue increase for Q2 2026, reaching about SEK 2.3 million, driven by strong U.S. sales and increased system deliveries. Despite the impressive revenue growth, the company's stock fell 3.29% in premarket trading, reflecting investor caution regarding its ongoing losses and the need for broader reimbursement support.Medical Device NetworkAcarix secures approval in UAE for CADScor systemSwedish medical device company Acarix has secured regulatory approval from the Emirates Drug Establishment and the Ministry of Health and Prevention for its CADScor system in the United Arab Emirates. The device will be launched commercially in the region through a partnership with UniTech Solutions, which will handle distribution and clinical support. This approval establishes a foothold for Acarix to potentially expand access to other Gulf Cooperation Council countries.YahooAcarix Receives Regulatory Approval for the CADScor® System in the UAE (United Arab Emirates)Acarix AB, a Swedish medical device company, has received regulatory approval from the Emirates Drug Establishment and the Ministry of Health and Prevention for its CADScor® System in the United Arab Emirates. The approval enables commercial availability of the rapid, non-invasive coronary artery disease diagnostic system through distribution partner UniTech Solutions. The company views the UAE as a gateway to the wider Gulf Cooperation Council region, where high case volumes and established clinical infrastructure drive demand for improved cardiac triage tools.Stock TitanAcarix Receives UAE Regulatory Approval for CADScorAcarix received regulatory approval for its CADScor System in the United Arab Emirates, enabling its commercial availability across the region. The system provides a rapid, non-invasive diagnostic tool for coronary artery disease, with a result time under 10 minutes.